Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023

Same author

Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021

Same author

Venous thromboembolism in cancer patients: a population-based cohort study.

Blood·2020

Same author

Thromboembolic and bleeding complications in patients with oesophageal cancer.

The British journal of surgery·2020

Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020

Same author

Perioperative bridging of anticoagulation: towards a more reserved approach.

The Netherlands journal of medicine·2019

Search research articles

Related Experiment Videos

Development in anticoagulant therapy.

F F van Doormaal¹, H R Büller, S Middeldorp

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. F.F.vanDoormaal@amc.uva.nl

Critical Reviews in Oncology/Hematology

|November 23, 2007

Summary

Venous thromboembolism (VTE) is a significant concern, particularly for cancer patients. Low-molecular weight heparin shows promise in managing VTE in this population, potentially offering advantages over traditional treatments.

Related Experiment Videos

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Venous thromboembolism (VTE) is a serious clinical issue.
Cancer patients face an elevated risk of developing VTE, and vice versa.
Current VTE treatments, heparin followed by vitamin K antagonists, have limitations.

Purpose of the Study:

To evaluate the efficacy and safety of low-molecular weight heparin (LMWH) in cancer patients with VTE.
To compare LMWH with vitamin K antagonists (VKAs) in this patient group.
To explore the potential anti-cancer properties of LMWH and the impact of novel anticoagulants on cancer progression and survival.

Main Methods:

Review of clinical data comparing LMWH monotherapy with VKAs in cancer patients with VTE.
Analysis of complication rates, including bleeding and VTE recurrence.
Consideration of ongoing clinical evaluations of novel anticoagulants.

Main Results:

Vitamin K antagonists (VKAs) present challenges in cancer patients due to a narrow therapeutic window, leading to bleeding or recurrent VTE.
Low-molecular weight heparin (LMWH) monotherapy appears to result in fewer complications compared to VKAs in cancer patients.
LMWH is also investigated for potential anti-cancer effects.

Conclusions:

LMWH demonstrates a potentially favorable profile for managing VTE in cancer patients compared to VKAs.
Novel anticoagulants require thorough evaluation for their effects on cancer progression and survival.
Further research is needed to optimize anticoagulation strategies in oncology.